Skip to main content
SpringerLink
Log in

Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics?

  • Clinical Pharmacology
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Ketanserin is a serotonin S2-receptor antagonist that is an effective antihypertensive agent with a greater blood pressure reduction in older patients. We have reviewed the data from two studies of ketanserin pharmacokinetics in elderly patients, one in general practice (GP) and one in hospital patients. We compared these data with the results from two of our previous studies in young volunteers. The purpose was to determine whether the enhanced efficacy of ketanserin in elderly hypertensive patients could be due to altered pharmacokinetics. After a single dose of ketanserin, elderly hypertensives showed about a 60% increase in bioavailability compared with young volunteers. This increase is likely to be explained by a reduced metabolism of ketanserin on first pass through the liver. The elimination half-life of ketanserin was found to be longer in elderly hospital outpatients, but not in our elderly subjects in general practice. This prolongation of the elimination half-life of ketanserin appears to be unrelated to age, since the hospital outpatient elderly and elderly subjects in general practice were of similar ages. The elimination half-life of ketanserinol was longer in the hospital elderly subjects. This probably reflects a slight diminution of renal function in the elderly hospital outpatients, resulting in reduced clearance of ketaserinol. The peak and trough ketanserin concentrations were similar in young and elderly subjects during chronic treatment, and it is therefore unlikely that the increased efficacy of ketanserin in elderly patients is due to altered pharmacokinetcs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cameron HA, Ramsay LER. Ketanserin in essential hypertension: A double blind placebo controlled study. Postgrad Med J 1985;61:583–586.

    Google Scholar 

  2. Korlipara K, Gould SE, Taylor NA, et al. Comparative trial of ketanserin of bendrofluazide as add-on therapy in hypertensive patients uncontrolled on a β-blocker alone. Drugs 1983;36(Suppl 1):130–134.

    Google Scholar 

  3. Rodendorff C, Murray GD. Ketanserin versus metoprolol and hydrochlorothiazide in essential hypertension: Only ketanserin's hypstansive effect is age related. J Hypertens 1986;4(Suppl 6):S109-S111.

    Google Scholar 

  4. Meuldermans W, Hendrickx J, Woestenborghs R, et al. Absorption, metabolism and excretion of ketanserin in man after oral administration. Arzneim-Forsch (Drug Research) 1988;38:789–794.

    Google Scholar 

  5. Frenken M, Kaumann AJ. Interaction of ketanserin and its metabolite ketanserinol with 5HT2 receptors in pulmonary and coronary arteries of calf. Naumyn-Schmiedeberg's Arch Pharmacol 1984;326:334–339.

    Google Scholar 

  6. Van Peer A, Woestenborghs R, Embrechts L, et al. Pharmacokinetic approach to equilibrium between ketanserin and ketanserin-ol. Eur J Clin Pharmacol 1986;31:339–342.

    Google Scholar 

  7. Ramsay LE, Tucker GT. Drugs and the elderly. Br Med J 1981;282:125–127.

    Google Scholar 

  8. Greenblatt DJ, Sellers FM, Shader RI. Drug disposition in old age. N Eng J Med 1985;306(18):1081–1088.

    Google Scholar 

  9. Heykants J, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of ketanserin and its metabolite ketanserinol in man after intravenous, intramuscular and oral administration. Eur J Clin Pharmacol 1986;31:343–350.

    Google Scholar 

  10. McGourty JC, Silas JH, Cowen KJ. Controlled trial of ketanserin in hypertension. Br J Clin Pharmacol 1985;20:37–40.

    Google Scholar 

  11. Okonkwo PO, Reimman IW, Woestenborghs R, et al. High performance liquid chromatographic assay, with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2-antagonist in human plasma, blood and urine. J Chromatogr 1983;272:411–416.

    Google Scholar 

  12. Kurowski M. Bioavailability and pharmacokinetics of ketanserin in elderly subjects. Eur J Clin Pharmacol 1985;28:411–417.

    Google Scholar 

  13. Barendregt JNM, Van Peer A, Van Oene JC, et al. Pharmacokinetics of ketanserin in patients with renal insufficiency. Data presented at 3rd Int Symposium on Hypertension in the Community, Tel Aviv, Israel, December 1988.

  14. Donnelly R, Elliott HL, Meredith PA, et al. Ketanserin in essential hypertension-individual response and concentration effect relationship. Br J Clin Pharmacol 1988;25(1):103P.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Janssen Pharmaceutical Ltd, Grove, Wantage, Oxon, UK

    Susan E. Gould

  2. Hypertension Unit, Clatterbridge Hospital, Bebington, Wirral, Merseyside, UK

    Joseph H. Silas

  3. 1980 Great Western Avenue, Glasgow, Scotland

    James Hosie

Authors
  1. Susan E. Gould
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph H. Silas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James Hosie
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gould, S.E., Silas, J.H. & Hosie, J. Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics?. Cardiovasc Drug Ther 4, 89–92 (1990). https://doi.org/10.1007/BF00053435

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00053435

Key words

Search

Navigation